Navigation Links
Biosensors International to Participate in the 30th Annual J.P. Morgan Healthcare Conference
Date:12/30/2011

SINGAPORE, Dec. 30, 2011 /PRNewswire-Asia/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG:SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices for interventional cardiology and critical care procedures, today announced it will be participating in the 30th Annual J.P. Morgan Healthcare Conference which will be held from 9th to 12th January 2012 in San Francisco, United States.

During this conference, the senior management of Biosensors will present on Thursday, January 12th, 2012 at 11:00am PST within the Asia Healthcare Company Track, and will also meet investors in scheduled one-on-one and small group meetings throughout the conference.

About Biosensors International Group, Ltd.

Listed on the Singapore Stock Exchange (SGX), Biosensors develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.

With the increasing use of the BioMatrix™ family of drug-eluting stents, we are rapidly emerging as a leader in the global coronary stent market. The recent launch of the Axxess™ self-expanding bifurcation drug-eluting stent and the development of the BioFreedom™ drug-coated stent will further reinforce our market position.

All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water over a six-to-nine-month period as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent platform specifically designed for treating bifurcation lesions. BioFreedom, a completely polymer‐free stent abluminally coated with BA9, is currently undergoing clinical evaluation.

For more information, please visit www.biosensors.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

For Biosensors International Group, Ltd.

Mr. Wong Teck Yenn
Director, Investor Relations
Tel: +65-6213-5708
Email: ty.wong@biosensors.com


'/>"/>
SOURCE Biosensors International Group, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Global Biosensors in Medical Diagnostics Industry
2. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
3. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
4. Chindex International, Inc. Announces Management Changes
5. Unprecedented International Effort Seeks to Improve Safety of Orthopedic Devices
6. Chindex International, Inc. Announces Opening of Latest Premium Hospital in Tianjin
7. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
8. Pharmacy Franchise Owners Association: Medicine Shoppe International and Medicap Face Claims Filed by Numerous Franchisees
9. SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases
10. International Isotopes Inc. Announces Conference Call to Give an Update on the Companys General Business Status
11. New MediCare International Excess Options Give up to 50% Premium Discount
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... It should come as no surprise to anyone ... the midst of a crippling opioid epidemic. According to the ... of overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... dead from 2001 to 2015". During this time, the prescription ... quadrupled, drawing a compelling link between prescription and eventual addiction. ...
(Date:7/13/2017)... ROCKVILLE, Md. , July 13, 2017  New York ... watchers of pharmaceutical markets should be aware of.  From new ... These trends are detailed in a recently completed study, ... following: 1.  Age-Driven ... years, we have been aware of the impact the growing ...
(Date:7/11/2017)... 11, 2017 Zymo Research Corp., also known as ,The Epigenetics ... biological aging in a precise manner using the myDNAge ™ test. ... a professor of human genetics and biostatistics at the David Geffen ... Health , Zymo Research,s proprietary DNAge ™ technology is used to ... ...
Breaking Medicine Technology:
(Date:7/24/2017)... Houston, TX (PRWEB) , ... July 24, 2017 , ... ... $1000 student scholarship will be awarded for the fall semester to a deserving student. ... SignatureCare Emergency Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... unique opportunity that helps high school girls succeed in STEM programs as well ... Horizon Goodwill will host over 20 high school girls at their corporate headquarters ...
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will host ... tremor (ET). The seminar will take place on Saturday, Aug. 26 at the Embassy ... program will run from 9 a.m. to 12 p.m., with check-in beginning at 8 ...
(Date:7/24/2017)... NY (PRWEB) , ... July 24, 2017 , ... ... series of media initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn ... elements is one of the leading causes of long term skin conditions, including ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global leader in ... of United States Patent Number 9,695,398 (the '398 patent) and South Korean Patent ... and '324 patents cover methods and systems for optimizing fat grafts for current ...
Breaking Medicine News(10 mins):